Functional neural correlates of anosognosia in Alzheimer s disease. University Medical Center Groningen

Similar documents
Form D1: Clinician Diagnosis

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT

Mild Cognitive Impairment (MCI)

Anosognosia and rehabilitation: Definitions, practice implications, and directions for future research. Nicole Matichuk* and Liv Brekke **

Molecular Imaging and the Brain

CSF Aβ1-42 predicts cognitive impairment in de novo PD patients

USE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Imaging of Alzheimer s Disease: State of the Art

Anosognosia, or loss of insight into one s cognitive

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

Brain imaging for the diagnosis of people with suspected dementia

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)

Patients with disorders of consciousness: how to treat them?

An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease

EPILESSIA Epidemiologia e inquadramento diagnostico. Ettore Beghi IRCCS Istituto Mario Negri, Milano

Form A3: Subject Family History

SHARED CARE OF MCI/EARLY DEMENTIA

Subject Index. Berkson bias 72

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline

Update on functional brain imaging in Movement Disorders

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

How can the new diagnostic criteria improve patient selection for DM therapy trials

Heterogeneous Data Mining for Brain Disorder Identification. Bokai Cao 04/07/2015

Neuropsychiatric symptoms as predictors of MCI and dementia: Epidemiologic evidence

Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation

Delirium in Older Persons: An Investigative Journey

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

Is PET/CT really helpful in diagnosing Alzheimer s Disease?

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge

European Prevention of Alzheimer s Dementia (EPAD)

review of existing studies on ASL in dementia Marion Smits, MD PhD

The Aging Brain The Aging Brain

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA

Delirium & Dementia. Nicholas J. Silvestri, MD

Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT

17 th WORKSHOP ON NEUROOTOLOGY. Dementia & Imbalance. DR. ATRI CHATTERJEE Assistant Professor. Neurology VMMC & SafdarJung Hospital New Delhi

Author's response to reviews

Depression: An Important Risk Factor for Cognitive Decline

Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre

HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?

A U. Methods of Cognitive Neuroscience 2/8/2016. Neat Stuff! Cognitive Psychology

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Erin Cullnan Research Assistant, University of Illinois at Chicago

Dementia Past, Present and Future

Neuroimaging for dementia diagnosis. Guidance from the London Dementia Clinical Network

Understanding Symptoms, Causes, and Risks for Alzheimer s Disease

The world is graying: Dementia is an alarming issue

The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease

This item is the archived peer-reviewed author-version of:

September 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by

I do not have any disclosures

The Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD

Alzheimer s Disease. Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby

Advances in Clinical Neuroimaging

NACC Minimum Data Set (MDS) Public Data Element Dictionary

Geri R Hall, PhD, GCNS, FAAN Advanced Practice Nurse Emeritus Banner Alzheimer s Institute

Postdoctoral and research scientist positions

Mentis Cura November

NEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES.

Imaging in Dementia:

Latest Methods to Early Detection for Alzheimer's: Cognitive Assessments and Diagnostic Tools in Practice

Alzheimer s Disease Neuroimaging Initiative

SATURDAY, SEPTEMBER 16, 2017

The Hellenic Longitudinal Investigation of Aging and Diet (HELIAD): study description and preliminary data

Disentangling Delirium and Dementia

Regulatory Challenges across Dementia Subtypes European View

OMICS Group. Contact us at:

tdcs in Clinical Disorders

The role of reality monitoring in anosognosia for hemiplegia. Christine Roffe 3 & Simon J. Ellis 5

Detection of Mild Cognitive Impairment using Image Differences and Clinical Features

Changing diagnostic criteria for AD - Impact on Clinical trials

Research and possible future brain health treatments

Multimodal Imaging in Extratemporal Epilepsy Surgery

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky

Computational and visual analysis of brain data

Recommendations for the Diagnosis and Treatment of Dementia 2012

3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion

Assessing and Managing the Patient with Cognitive Decline

Mild Cognitive Impairment

Alzheimer s Disease without Dementia

TGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci

Personal Reflections on the Design and Delivery of Services to Those with Cognitive Disorders

Recent publications using the NACC Database. Lilah Besser

Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias

The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease

3 COMMON PSYCHIATRIC DISORDERS IN OLDER ADULTS: NEW INSIGHTS

Assessing Cognition. Andreana Haley, Ph.D. Department of Psychology University of Texas at Austin

Can aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators

Evaluations. Alzheimer s Disease A Public Health Response. Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors:

Claims & Underwriting. You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association

Engineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos,

The added value of the IWG-2 diagnostic criteria for Alzheimer s disease

Advances in Alzheimer s diagnosis; implications for clinical practice. Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017

Moving Targets: An Update on Diagnosing Dementia in the Clinic

Il processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D.

Neuroscience of Consciousness II

ANOSOGNOSIA FOR HEMIPLEGIA. Theoretical, Clinical, and Neural Aspects AHP: THEORETICAL, CLINICAL, AND NEURAL ASPECTS 1

FDG-PET e parkinsonismi

JOURNAL RANKING 2014 FOR BEHAVIORAL SCIENCES

Transcription:

Functional neural correlates of anosognosia in Alzheimer s disease Jaime D. Mondragón M.D., M.S. Prof. Dr. Natasha M. Maurits Prof. Dr. Peter P. De Deyn April 13 th, 2018 Department of Neurology Clinical Neuroengineering Alzheimer Research Center Groningen University Medical Center Groningen

Outline 1. Introduction Impact Biomarkers Imaging modalities Anosognosia 2. Results Neural correlates of anosognosia Past and Future projects

Impact, Biomarkers, Imaging Modalities, and Anosognosia INTRODUCTION

Impact Alzheimer s disease Estimated worldwide cost (billions of dollars) 35,6 million worldwide (2010) 54% developing countries 60-80% of dementias World estimated prevalence 2030: 65,7 million 2050: 115,4 million Mexico 2030: 2,7 million 1200 1000 800 600 400 200 0 2007 2009 2010 2030 Direct and indirect costs Jack Jr et al. (2013). Lancet Neurology; 12: 207-16. Sosa-Ortiz et al. (2012). Archives of medical research; 43: 600-8. Wimo et al. (2013). Alzheimer & Dementia; 9: 1-13.

Model of dynamic biomarkers Biological o o CSF Serum Bateman et al. (2012). N Engl J Med.; 367(9): 795-804. Jack Jr et al. (2013). Lancet Neurology; 12: 207-16.

Model of dynamic biomarkers Imaging o o Structural Functional Bateman et al. (2012). N Engl J Med.; 367(9): 795-804. Jack Jr et al. (2013). Lancet Neurology; 12: 207-16.

Multifactorial causal model Iturria-Medina et al. (2016). Nat. Commun; 7: 1-14. Iturria-Medina et al. (2017). Neuroimage; 152: 60-77.

Overview of neuroimaging modalities Grinvald and Hildesheim. (2004). Nature reviews neurosci; 5(11): 874-55.

Anosognosia From the Greek, α = without, νόσϛ = disease, γνώσιϛ = knowledge Joseph Babinski in 1914, Revue Neurologie Dorland s medical dictionary Unawareness or denial of a neurological deficit such as hemiplegia The lack of awareness of motor, visual or cognitive deficits in patients with neurological diseases Di Perri et al. (2014). Epilepsy Behav; 30: 28-32. Dorland and Newman. (2012). Dorland's illustrated medical dictionary; 32: 96. Nurmi and Jehkonen. (2014). Cortex; 61: 43-63.

Anosognosia classification Subtypes or etiology: Hemiplegic, cortical blindness, Anton s syndrome, visual field defect, traumatic brain injury, multiple sclerosis, Parkinson s disease, Alzheimer s disease, mild cognitive impairment, frontotemporal dementia and Huntington s disease. Anosognosia in Alzheimer s disease Anosognosia Questionnaire-Dementia (AQ-D) Dementia Deficits Scale (DDS) Adjusted Memory Awareness Rating Scale (MARSA) Vannini et al. (2017). Neuropsychologia; 99: 343 9. Nurmi and Jehkonen. (2014). Cortex; 61: 43-63.

Neural Correlates of Anosognosia RESULTS

Neural correlates of anosognosia Systematic review PubMed, EMBASE and PsycINFO on March 2018 Identical research strategy with a priori variables was realized on each database following the PRISMA statement (Moher et al., 2009). Keywords: anosognosia, self-appraisal, insight, awareness, and consciousness combined with each of the following terms dementia, Alzheimer, mild cognitive impairment Supplementary search was performed using MRI, PET, SPECT, connectivity, activation, hypometabolism, and hypermetabolism. Mondragón et al. (2018). Neurosci Biobehav Rev.; in press.

Highlights Abnormal frontotemporal activity occurs in MCI and AD with anosognosia MCI patients with anosognosia (MCIwa) have reduced parietotemporal metabolism MCIwa have reduced cortical midline (CM) perfusion and activation Anosognosia in AD reduces DMN activation and within network connectivity Reduced neural activity pattern in anosognosia: CM, parietotemporal, frontotemporal Mondragón et al. (2018). Neurosci Biobehav Rev.; in press.

Neural correlates of anosognosia Figure 2. Graphical representation of the neural correlates in MCI patients with anosognosia. Mondragón et al. (2018). Neurosci Biobehav Rev.; in press.

Neural correlates of anosognosia Figure 3. Graphical representation of the neural correlates of unawareness in MCI. Mondragón et al. (2018). Neurosci Biobehav Rev.; in press.

Neural correlates of anosognosia Figure 4. Graphical representation of the neural correlates in mild to moderate AD patients with anosognosia. Mondragón et al. (2018). Neurosci Biobehav Rev.; in press.

Neural correlates of anosognosia Figure 5. Graphical representation of the neural correlates of unawareness in mild to moderate AD. Mondragón et al. (2018). Neurosci Biobehav Rev.; in press.

Mondragón et al. (2018). Neurosci Biobehav Rev.; in press.

Hippocampal volume Mondragón et al. (2016). Dement Geriatr Cogn Dis Extra; 6: 486-99.

Hippocampal volume Mondragón et al. (2016). Dement Geriatr Cogn Dis Extra; 6: 486-99.

Hippocampal volume Mondragón et al. (2016). Dement Geriatr Cogn Dis Extra; 6: 486-99.

Future projects Neural correlates of anosgnosia in Alzheimer s Disease Neuroimaging Initiative Neural correlates of anosgnosia in Parelsnoer Initiative